KPRX

Insider Trades

Name	Value	Action	Price	Current Price
Stengone Carmine N.Director $4.6k1.3k shares BuySep 11, 2024 $3.68 --
Shapiro AronDirector $11k3k shares BuySep 10, 2024 $3.60 --
Walters-Hoffert LisaDirector $4.8k1.3k shares BuyAug 19, 2024 $3.86 --
Tyle PraveenDirector $20k5k shares BuyAug 19, 2024 $3.96 --
Tosca MelissaCFO $6.4k2k shares BuyAug 14, 2024 $3.21 --
Tosca MelissaEVP Finance $525100 shares BuyJun 14, 2024 $5.25 --

News

newsfilecorp.comKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Modelnewsfilecorp.comJun 18

newsfilecorp.comKiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Updatenewsfilecorp.comMay 8

newsfilecorp.comKiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underwaynewsfilecorp.comApr 14

defenseworld.netFinancial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)defenseworld.netApr 14

newsfilecorp.comKiora Pharmaceuticals Announces Management Team Changesnewsfilecorp.comApr 2

Trade KPRX

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

CEO: Brian Strem
IPO Date: Feb 13, 2015

Market Data

Open: $2.63
High: $2.71
Low: $2.53
Volume: 94.9K
Avg Volume: 492K
52W High: $3.29
52W Low: $1.77

Valuation

Market Cap: $11M
Enterprise Value: $631k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-10M
Revenue: $0
Net Income: $-11M
Cash: $8.7M
Debt: $368k

Events

EarningsAug 7

EPS est. -0.47